On June 24, 2026, FDA issued Warning Letter 320-26-97 to Wizcure Pharmaa Private Limited in Bhiwadi, Rajasthan, India, following an inspection conducted December 3 to 10, 2025 — a ten-day inspection that documented one of the most direct forms of data falsification FDA investigators encounter: the physical replacement of incubating microbial plates showing growth with fresh plates showing no growth. FDA had already placed Wizcure on Import Alert 66-40 on December 23, 2025, thirteen days after the inspection closed, a timeline that reflects how seriously the agency assessed the safety risk.
The primary citation in Warning Letter 320-26-97 is 21 CFR 211.194(a) — failure to ensure that laboratory records include complete data derived from all tests necessary to ensure compliance with established specifications and standards. The specific conduct FDA documented is unambiguous. During the inspection, FDA investigators observed personnel monitoring microbial plates in the laboratory incubator showing visible microbial growth. The following day, those same plates — identifiable by their sample identification information — showed no growth. Both management and a microbiologist at the facility confirmed that the original plates had been discarded and replaced with new plates. This is not a documentation gap or a record keeping deficiency. It is a deliberate substitution of a contaminated sample result with a clean one in a context where the result directly determined whether an aseptic processing line was in environmental control during drug product manufacturing.
The ALCOA+ framework that governs data integrity under FDA’s 2018 Data Integrity and Compliance with Drug CGMP Guidance requires that every data record be Attributable, Legible, Contemporaneous, Original, Accurate, Complete, Consistent, Enduring, and Available. The destruction and replacement of positive microbial plates violates five of these nine attributes simultaneously: the replacement plates are not Original (the original incubation data has been destroyed), not Contemporaneous (they were created after the incubation event), not Accurate (they do not reflect the actual microbiological state of the sample), not Complete (the original result is absent from the record), and not Consistent (the record now contradicts the observable state that FDA investigators documented on the prior day). Under 21 CFR 211.194(a)(8), laboratory records must be complete, accurate, and attributable to the individuals performing the activity. No remediation action can restore completeness or accuracy to records that have been physically destroyed.
The significance of this specific falsification extends beyond the data record itself. Environmental and personnel monitoring in an aseptic processing facility is the primary real-time control system for detecting contamination events before they affect sterile product. Under the FDA 2004 Aseptic Processing Guidance, environmental monitoring alert and action levels must be statistically derived from facility performance data and must trigger investigations when exceeded. The purpose of those investigations is to identify contamination sources, assess product impact, and implement corrective actions before microbial contamination reaches the product exposure zone. When personnel monitoring plates showing growth are replaced with clean plates, that control system is disabled at the exact moment it was generating a signal. Any batches manufactured during the period covered by falsified EM/PM data cannot be assessed for environmental state-of-control during their production, because the actual monitoring data has been destroyed.
Wizcure’s aseptic processing infrastructure failures, cited under 21 CFR 211.42(c)(10), compounded the contamination risk that the falsified data concealed. FDA documented that the filling line had no physical barrier separating the ISO 5 Grade A aseptic filling zone from the surrounding ISO 7 Grade B room and its personnel. The absence of a physical barrier between ISO 5 and ISO 7 in an aseptic filling operation means that personnel movement, air turbulence, and particle generation in the ISO 7 environment have unobstructed access to the critical zone where sterile product is exposed. Equipment components in direct contact with drug product, containers, and closures were not sterilized. The aseptic processing room lacked adequate space for ergonomic personnel and material flow. Manufacturing equipment was in poor state of repair, including visible rust on critical aseptic processing components and on HEPA filters and their diffuser grids above the filling line. An HEPA filter diffuser with apparent rust is a visible indicator of surface degradation in the primary contamination control barrier for the ISO 5 zone.
FDA also cited deficiencies under 21 CFR 211.113(b) for aseptic process simulation failures. Wizcure’s media fills were not sufficiently representative of commercial aseptic manufacturing operations — batch records lacked documentation of all personnel present and all interventions during aseptic manufacturing, and airflow visualization studies were performed under static rather than dynamic conditions. Static smoke studies do not reveal the airflow perturbations created by actual aseptic interventions, which is precisely the information needed to assess contamination risk from routine and non-routine operations. An aseptic process simulation that does not document interventions and is not evaluated under dynamic conditions provides no meaningful assurance that the commercial aseptic process is under control.
The enforcement resolution was rapid and comprehensive. FDA placed the facility on Import Alert 66-40 on December 23, 2025 — thirteen days after the inspection closed. FDA held a teleconference recommending voluntary recall of all sterile OTC drug products in US distribution. Wizcure committed to cease manufacturing and distribution for the US market and agreed to voluntary recall of all distributed drugs. Production remains suspended. For a manufacturer of OTC sterile drug products supplying the US market, this sequence — data falsification finding, Import Alert 66-40 within two weeks, voluntary recall — reflects FDA’s assessment that the facility’s quality system could not be trusted to make any disposition decision with reliability.
The remediation path for a facility with confirmed data falsification is fundamentally different from one with documentation deficiencies or technical CGMP failures. Under FDA’s 2018 Data Integrity Guidance, a site where data falsification has been confirmed must implement a comprehensive data integrity remediation program: a retrospective audit of all data generated under the conditions that allowed falsification to occur, an independent assessment of the quality culture that permitted those actions, structural controls that make falsification physically impossible (audit trail systems with institutional controls, dual verification of monitoring data, independent quality oversight of all critical test results), and a demonstrated period of reliable data generation before FDA will consider resuming import authorization. None of these steps is procedural; each requires sustained organizational commitment and, typically, qualified external oversight.
For OTC sterile drug manufacturers and their contract development partners, the Wizcure case illustrates why data integrity remediation programs must begin with an honest organizational assessment. The falsification documented here — discarding plates and replacing them — required management knowledge, as confirmed by FDA’s interview findings. That means the corrective action must address not just the procedure that was violated, but the management environment that allowed personnel to believe the falsification was acceptable or unavoidable. XGene’s data integrity remediation practice supports pharmaceutical manufacturers through the full arc of recovery: root cause assessment at the organizational level, retrospective data audit program design, ALCOA+-compliant quality system implementation, and FDA reinspection preparation.